Ala Yaromina

List of Publications by Year
in descending order

36 papers	1,261 citations	331259 21 h-index	360668 35 g-index
36 all docs	36 docs citations	36 times ranked	1945 citing authors

#	Article	IF	Citations
1	Prognostic Significance of Carbonic Anhydrase IX Expression in Cancer Patients: A Meta-Analysis. Frontiers in Oncology, 2016, 6, 69.	1.3	129
2	Combining radiotherapy with immunotherapy: the past, the present and the future. British Journal of Radiology, 2017, 90, 20170157.	1.0	99
3	TH-302 in Combination with Radiotherapy Enhances the Therapeutic Outcome and Is Associated with Pretreatment [18F]HX4 Hypoxia PET Imaging. Clinical Cancer Research, 2015, 21, 2984-2992.	3.2	95
4	Hypoxia-activated prodrugs and (lack of) clinical progress: The need for hypoxia-based biomarker patient selection in phase III clinical trials. Clinical and Translational Radiation Oncology, 2019, 15, 62-69.	0.9	86
5	Radiotherapy Combined with the Immunocytokine L19-IL2 Provides Long-lasting Antitumor Effects. Clinical Cancer Research, 2015, 21, 1151-1160.	3.2	79
6	New ways to image and target tumour hypoxia and its molecular responses. Radiotherapy and Oncology, 2015, 116, 352-357.	0.3	49
7	HIF-1Î± and HIF-2Î± Differently Regulate the Radiation Sensitivity of NSCLC Cells. Cells, 2019, 8, 45.	1.8	48
8	Prognostic Role of Hypoxia-Inducible Factor-2Î± Tumor Cell Expression in Cancer Patients: A Meta-Analysis. Frontiers in Oncology, 2018, 8, 224.	1.3	43
9	Î³H2AX assay in ex vivo irradiated tumour specimens: A novel method to determine tumour radiation sensitivity in patient-derived material. Radiotherapy and Oncology, 2015, 116, 473-479.	0.3	38
10	Residual Î³H2AX foci after ex vivo irradiation of patient samples with known tumour-type specific differences in radio-responsiveness. Radiotherapy and Oncology, 2015, 116, 480-485.	0.3	37
11	The immunocytokine L19-IL2: An interplay between radiotherapy and long-lasting systemic anti-tumour immune responses. OncoImmunology, 2018, 7, e1414119.	2.1	36
12	Hypoxia PET Imaging with [18F]-HX4â€"A Promising Next-Generation Tracer. Cancers, 2020, 12, 1322.	1.7	35
13	Effect of [18F]FMISO stratified dose-escalation on local control in FaDu hSCC in nude mice. Radiotherapy and Oncology, 2014, 111, 81-87.	0.3	34
14	Synthesis and in Vivo Biological Evaluation of ⁶⁸Ga-Labeled Carbonic Anhydrase IX Targeting Small Molecules for Positron Emission Tomography. Journal of Medicinal Chemistry, 2016, 59, 6431-6443.	2.9	33
15	Combination of radiotherapy with the immunocytokine L19-IL2: Additive effect in a NK cell dependent tumour model. Radiotherapy and Oncology, 2015, 116, 438-442.	0.3	30
16	Hypoxia-Inducible Factor Pathway Inhibition Resolves Tumor Hypoxia and Improves Local Tumor Control After Single-Dose Irradiation. International Journal of Radiation Oncology Biology Physics, 2014, 88, 159-166.	0.4	29
17	Human fibronectin extra domain B as a biomarker for targeted therapy in cancer. Molecular Oncology, 2020, 14, 1555-1568.	2.1	29
18	Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial. BMC Cancer, 2020, 20, 557.	1.1	29

#	Article	IF	Citations
19	Novel fluorinated carbonic anhydrase IX inhibitors reduce hypoxia-induced acidification and clonogenic survival of cancer cells. Oncotarget, 2018, 9, 26800-26816.	0.8	25
20	Charged Particle and Conventional Radiotherapy: Current Implications as Partner for Immunotherapy. Cancers, 2021, 13, 1468.	1.7	24
21	Preclinical Assessment of Efficacy of Radiation Dose Painting Based on Intratumoral FDG-PET Uptake. Clinical Cancer Research, 2015, 21, 5511-5518.	3.2	23
22	A novel co-culture assay to assess anti-tumor CD8+ T cell cytotoxicity via luminescence and multicolor flow cytometry. Journal of Immunological Methods, 2020, 487, 112899.	0.6	23
23	Releasing the brakes of tumor immunity with anti-PD-L1 and pushing its accelerator with L19â€“IL2 cures poorly immunogenic tumors when combined with radiotherapy. , 2021, 9, e001764.		23
24	A novel concept for tumour targeting with radiation: Inverse dose-painting or targeting the â€œLow Drug Uptake Volumeâ€. Radiotherapy and Oncology, 2017, 124, 513-520.	0.3	22
25	New approach of delivering cytotoxic drugs towards CAIX expressing cells: A concept of dual-target drugs. European Journal of Medicinal Chemistry, 2017, 127, 691-702.	2.6	22
26	Synergistic Effects of NOTCH/Î³-Secretase Inhibition and Standard of Care Treatment Modalities in Non-small Cell Lung Cancer Cells. Frontiers in Oncology, 2018, 8, 460.	1.3	22
27	Evofosfamide sensitizes esophageal carcinomas to radiation without increasing normal tissue toxicity. Radiotherapy and Oncology, 2019, 141, 247-255.	0.3	19
28	An orthotopic non-small cell lung cancer model for image-guided small animal radiotherapy platforms. British Journal of Radiology, 2019, 92, 20180476.	1.0	17
29	Selectively Targeting Tumor Hypoxia With the Hypoxia-Activated Prodrug CP-506. Molecular Cancer Therapeutics, 2021, 20, 2372-2383.	1.9	17
30	The Sulfamate Small Molecule CAIX Inhibitor S4 Modulates Doxorubicin Efficacy. PLoS ONE, 2016, 11, e0161040.	1.1	14
31	Combining hypoxia-activated prodrugs and radiotherapy in silico: Impact of treatment scheduling and the intra-tumoural oxygen landscape. PLoS Computational Biology, 2020, 16, e1008041.	1.5	13
32	Nitroglycerin as a radiosensitizer in non-small cell lung cancer: Results of a prospective imaging-based phase II trial. Clinical and Translational Radiation Oncology, 2020, 21, 49-55.	0.9	11
33	Role of hypoxia-activated prodrugs in combination with radiation therapy: An <i>in silico</i> approach. Mathematical Biosciences and Engineering, 2019, 16, 6257-6273.	1.0	11
34	Impact of pre- and early per-treatment FDG-PET based dose-escalation on local tumour control in fractionated irradiated FaDu xenograft tumours. Radiotherapy and Oncology, 2016, 121, 447-452.	0.3	8
35	Therapeutic options to overcome tumor hypoxia in radiation oncology. Clinical and Translational Imaging, 2017, 5, 455-464.	1.1	6
36	Value of functional in-vivo endpoints in preclinical radiation research. Radiotherapy and Oncology, 2021, 158, 155-161.	0.3	3